Costs of a successful public-private partnership for TB control in an urban setting in Nepal.

BMC Public Health

Nuffield Centre for International Health and Development, Leeds Institute of Health Sciences and Public Health Research, University of Leeds, Leeds, UK.

Published: May 2007

Background: In South Asia a large number of patients seek treatment for TB from private practitioners (PPs), and there is increasing international interest in involving PPs in TB control. To evaluate the feasibility, effectiveness and costs of public-private partnerships (PPPs) for TB control, a PPP was developed in Lalitpur municipality, Nepal, where it is estimated that 50% of patients with TB are managed in the private sector. From the clinical perspective the PPP was shown to be effective. The aim of this paper is to assess and report on the costs involved in the PPP scheme.

Methods: The approach to costing took a comprehensive view, with inclusion of costs not only incurred by health facilities but also social costs borne by patients and their escorts. Semi-structured questionnaires and guided interviews were used to collect start-up and recurrent costs for the scheme.

Results: Overall costs for treating a TB patient under the PPP scheme averaged US$89.60. Start-up costs per patient represented 12% of the total budget. Half of recurrent costs were incurred by patients and their escorts, with institutional costs representing most of the rest. Female patients tended to spend more and patients referred from the private sector had the highest reported costs.

Conclusion: Treating TB patients in the PPP scheme had a low additional cost, while doubling the case notification rate and maintaining a high success rate. Costs incurred by patients and their escorts were the largest contributors to the overall total. This suggests a focus for follow-up studies and for cost-minimisation strategies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1888703PMC
http://dx.doi.org/10.1186/1471-2458-7-84DOI Listing

Publication Analysis

Top Keywords

costs incurred
12
patients escorts
12
costs
11
patients
8
private sector
8
recurrent costs
8
ppp scheme
8
incurred patients
8
ppp
5
costs successful
4

Similar Publications

Public Health.

Alzheimers Dement

December 2024

University of Maryland School of Public Health, College Park, MD, USA.

Background: Despite the growing number and proportion of the immigrant population in the US, there is a lack of knowledge on healthcare expenditures among immigrants with cognitive limitations or Alzheimer's disease and related dementias (ADRD). This study estimated differences in total healthcare expenditures between US-born and foreign-born individuals by the presence of ADRD and/or cognitive limitations. This study also examined the differences in healthcare expenditures by service types, including inpatient stays, office-based visits, emergency department (ED) visits, home healthcare, and prescription drugs.

View Article and Find Full Text PDF

Public Health.

Alzheimers Dement

December 2024

Karolinska Institutet, Solna, Stockholm, Sweden.

Background: Recent developments in blood biomarkers (BBM) have shown promising results in diagnosing amyloid pathology in Alzheimer's Disease (AD). However, information on how these BBMs can best be used in clinical settings to optimise clinical decision-making and long-term health outcomes for individuals with AD is still lacking. We aim to assess the potential clinical and economic value of BBM in AD diagnosis within the context of disease-modifying treatment (DMT).

View Article and Find Full Text PDF

Public Health.

Alzheimers Dement

December 2024

University of Maryland School of Public Health, College Park, MD, USA.

Background: Black and Hispanic ADRD patients often incur substantially higher costs related to Alzheimer's disease and related dementia (ADRD). Neighborhood-level vulnerabilities are also linked to increased risks of adverse health conditions. Emerging evidence has suggested that Accountable Care Organizations (ACOs) work effectively to promote ADRD care.

View Article and Find Full Text PDF

A review of the empirical evidence for costs of plasticity in ectothermic animals.

J Exp Biol

January 2025

School of Life and Environmental Sciences, A08 , University of Sydney, Sydney, NSW 2006, Australia.

Phenotypic plasticity can represent a vital adaptive response to environmental stressors, including those associated with climate change. Despite its evolutionary advantages, the expression of plasticity varies significantly within and among species, and is likely to be influenced by local environmental conditions. This variability in plasticity has important implications for evolutionary biology and conservation physiology.

View Article and Find Full Text PDF

Introduction: Squamous cell carcinoma is a major public health concern, with traditional treatments such as surgery, chemotherapy, and radiation therapy frequently resulting in significant side effects. Immunotherapy targeting checkpoints such as PD-1, CTLA-4, and B7- H3 provides a more specific approach but incurs high costs due to monoclonal antibodies.

Aim And Objective: This study aims to investigate the potential of natural flavonoids as lowtoxicity, small molecule-based alternatives targeting the PD-1 immunological checkpoint for SCC treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!